There is still significant unmet medical need in the few established immunomodulatory therapies within Innovimmune’s core therapeutic areas for Autoimmune Diseases and Inflammation. The limited therapies available today are mostly biologics directed against cytokines, cytokine receptors and the T-cell/B-cell immune compartments. These treatment modalities, however, have significant limitations related to inflexible drug delivery options, safety & toxicity (risk of opportunistic infection, cancer), moderate-to-limited efficacy, and prohibitive costs which limit their long-term maintenance use and tolerability for patients. The challenge in immunomodulatory drug development has been to selectively target a specific Mechanism of Action [MOA] that limits disease progression without the unwanted toxicities due to non-specific generalized immunosuppression.

Despite the diverse clinical manifestations of these therapeutic areas of interest, they share a unique common disease pathogenesis characterized by organ & tissue damage arising from the dysregulated immune responses and production of critical cytokines & chemokines, and downstream signal transduction events. Oral small molecule-based therapies directed against these important biological targets are therefore being intensively sought, as they provide ease of administration and flexible drug delivery options making them ideal as new treatment intervention modalities in Autoimmune and Inflammatory Diseases. Innovimmune's goal is to discover and develop first-in-class or best-in-class NME immunotherapies directed against the cytokine/chemokine network and signal transduction mechanisms that are selective and highly-specific to the overlapping disease pathways.


Innovimmune’s target disease indications within our core specialty therapeutic areas are:

Autoimmune & ImmunoInflammation Diseases
Rheumatoid Arthritis [RA]
Psoriasis/Psoriatic Arthritis
Crohn’s Disease [CD]
Ulcerative Colitis [UC]
Type 1 Diabetes

Solid Tumors

Multiple Sclerosis [MS]
Alzheimer’s Disease

Cardiovascular & Metabolic Diseases
Type 2 Diabetes